KRAS and cancer: Similarly, median OS was significantly shorter in patients with KRAS G12C–positive cancer with mSTK11-mKEAP1 vs STK11 WT-KEAP1 WT (5.0 vs 10.9 months; aHR, 2.20; 95% CI, 1.27–3.81; p = 0.005) (Fig. 4D).